A Phase 2 interventional study of Ketamine infusion in Anorexia Nervosa and Atypical Anorexia Nervosa, sponsored by Amanda Downey, MD. Enrolling by invitation at 1 site in United States. Open to participants aged 16 Years to 26 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Amanda Downey, MD · Phase 2, Interventional, and Treatment
This is a single site, single dose clinical trial of intravenous (IV) ketamine for medically hospitalized adolescents and young adults with anorexia nervosa or atypical anorexia nervosa. Eating disorder symptoms will be measured pre- and post-ketamine infusion. Investigators hypothesize that ketamine will increase cognitive flexibility, making medical hospitalizations less distressing by improving the ability to learn new, positive associations with food.
Exclusion Criteria:
Drug: Ketamine infusion
Ketamine will be delivered intravenously at 0.5 mg/kg over 40 minutes.
Mean Change From Baseline in Reversal Learning
Mean change in reversal learning as measured by the probabilistic reversal learning task.In the task, participants are presented with two stimuli, told to choose one of the two stimuli on each trial, and receive feedback regarding whether the stimulus is "Correct" or "Incorrect." Participants must modify their choice based on c hanging stimulus-outcome contingencies over time, engaging flexible learning.
Time frame: Day 2, Day 4
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.